James Flanagan

Imperial College London

Dr James Flanagan, completed his PhD in 2002 at the Queensland Institute of Medical Research in Brisbane, Australia, and has pursued postdoctoral work in Cancer Genetics, Epigenetics and Cancer Epigenetics. He was awarded a Breast Cancer Campaign Scientific Fellowship (Imperial, 2009-2014) and is now a Senior Lecturer (2014-present) in the Division of Cancer, Dept. of Surgery and Cancer, Faculty of Medicine at Imperial College London. He was awarded the British Association of Cancer Research Translational Researcher Award in 2011 and is the principal investigator for the OCA funded programme "Risk and Prevention" based in the Ovarian Cancer Action Research Centre. Current research is aimed at investigating epigenetic alterations as a mechanism for carcinogenesis and investigating the hypothesis that epigenetic variation may be a driver of cancer risk whether by inherent constitutional variation or as a mediator of other cancer risk factors.

dont miss

Epigenetic biomarkers for platinum response in ovarian cancer

Platinum based chemotherapy is the standard of care for ovarian cancer patients at first line treatment and often at subsequent relapses. We have identified and validated an epigenetic biomarker detectable in blood DNA that predicts whether a patient should be treated with platinum after relapse. We propose a mechanism by which platinum-adduct DNA repair causes the epigenetic changes and that the genomic and epigenomic location of platinum adducts defines sensitivity.

EVEN MORE SEMINARS

  • Dr Ndaba Mazibuko: Speaking at the Oncology Convention

    Dr Ndaba Mazibuko
    Care Oncology Clinic, Kings College London

    Drug Repurposing In Practice: Metabolic Pleiotropism in Glioblastoma Management

  • Glenn Flux: Speaking at the Oncology Convention

    Glenn Flux
    Royal Marsden Hospital

    The emergence and resurgence of radiotherapeutics for cancer treatment

  • Laura Allington: Speaking at the Oncology Convention

    Laura Allington
    University College London Hospitals NHS Foundation Trust

    Operational challenges of planning a new NHS high energy proton service.

  • Professor Patricia Price: Speaking at the Oncology Convention

    Professor Patricia Price
    Action Radiotherapy

    Action Radiotherapy -a charity for radiotherapy patients and professionals.

  • Richard Edwards BSc MBBS FRCS FRCS MD : Speaking at the Oncology Convention

    Richard Edwards BSc MBBS FRCS FRCS MD
    Circle Bath Hospital

    Coming soon...